the aid library - It's Over 9000!

LIST OPTIONS

Filter

2834

Download (416)

View PDF (1404)

Guidelines for Cunducting Clinical Trials of Medicines, Food Supplements, Vaccines, and Medical Devices in Sierra Leone

Pharmacy Board Sierra Leone (2014) C1

Download (477)

View PDF (1009)

Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products Bangladesh

Directorate General of Drug Administration,, Ministry of Health and Family Welfare, People's Republic of Bangladesh (2015) C1

Download (561)

View PDF (623)

Sierra Leone: Guidelines for Conducting Clinical Trials of Medicinal Products and Vaccines

Pharmacy Board Sierra Leone (2014) C1

Download (175)

View PDF (342)

Optimized Supportive Care for Ebola Virus Disease
recommended

World Health Organization WHO (2019) C_WHO

Clinical management standard operating procedures. Ebola virus disease (EVD) is a life-threatening multisystem illness associated with fever and gastrointestinal (GI) symptoms that frequently leads to hypovolaemia, metabolic acidosis, hypoglycaemia, and multi-organ failure. The prolonged 2013–201... more

Download (555)

View PDF (1168)

Guideline for Application to conduct Clinical Trials in Liberia

Liberia Medicines and Health Products Regulatory Authority (LMHRA) (2014) C1

Download (521)

View PDF (1131)

Ghana: GUIDELINES FOR REPORTING ADVERSE REACTION

Food and Drugs Authority (FDA), Ghana (2016) C2

Document No. : FDA/SMC/SMD/GL-RAR/2013/01

Download (849)

View PDF (949)

GUIDELINES FOR CONDUCTING CLINICAL TRIALS OF MEDICINES, FOOD SUPPLEMENTS, VACCINES AND MEDICAL DEVICES IN GHANA

Food and Drugs Authority (FDA), Ghana (2013) C1

Document No. : FDA/SMC/CTD/GL-CCT/2013/01

Download (384)

View PDF (1109)

Guidelines for conduct of clinical trials in Kenya

Pharmacy and Poisons Board, Ministry of Health, Kenya (2016) C1

Download (443)

View PDF (963)

Zambia: GUIDELINES ON REGULATING THE CONDUCT OF CLINICAL TRIAL IN HUMAN PARTICIPANTS

Zambia Medicines Regulatory Authority (ZAMRA) (2016) C2

First Edition

Download (2868)

View PDF (1107)

GUIDELINES FOR GOOD CLINICAL TRIAL PRACTICE IN ZIMBABWE

Medicines Control Authority of Zimbabwe (MCAZ) (2012) C2

Download (196)

View PDF (1188)

Nigeria: Good Clinical Practice Guidelines

National Agency for Food and Drugs Administration and Control (NAFDAC) (2016) C2

Download (181)

View PDF (352)

Guidelines for laboratory and field testing of molluscicides for control of schistosomiasis

World Health Organization WHO (2019) C_WHO

This document provides up-to-date guidance on laboratory studies as well as smallscale (semi-field) and large-scale field trials to assess the efficacy and determine field application rates of new molluscicide products for control of schistosomiasis.

Download (45)

View PDF (81)

WHO Living guideline: Drugs to prevent COVID-19
recommended

World Health Organization WHO (2021) C_WHO

Interim guidance 2 march 2021 Current use of drugs to prevent COVID-19 is variable, reflecting large-scale uncertainty. Numerous randomized trials of many different drugs are underway to inform practice. This first version of the Drugs to prevent COVID-19: A WHO living guideline contains new inform... more

Download (29)

View PDF (706)

A living WHO guideline on drugs for covid-19
recommended

Rochweg, B.; et al. (2021) CC

BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379 Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE... more

Download (32)

View PDF (1060)

Reducing surgical site infections in low-income and middle-income countries (FALCON): a pragmatic, multicentre, stratified, randomised controlled trial

Biccard, B.M.; V. Msosa, A.L Samateh et al. TheLancet (2021) CC

Surgical site infection (SSI) is the most common postoperative complication worldwide. WHO guidelines to prevent SSI recommend alcoholic chlorhexidine skin preparation and fascial closure using triclosan-coated sutures, but called for assessment of both interventions in low-resource settings. This s... more

Download (74)

View PDF (109)

Government policy interventions to reduce human antimicrobial use: A systematic review and evidence map

Van Katwyk, S. R.; Grimshaw, J. M.; et al (2019) C2

BACKGROUND: Growing political attention to antimicrobial resistance (AMR) offers a rare opportunity for achieving meaningful action. Many governments have developed national AMR action plans, but most have not yet implemented policy interventions to reduce antimicrobial overuse. A systematic evidenc...e map can support governments in making evidence-informed decisions about implementing programs to reduce AMR, by identifying, describing, and assessing the full range of evaluated government policy options to reduce antimicrobial use in humans. METHODS AND FINDINGS: Seven databases were searched from inception to January 28, 2019, (MEDLINE, CINAHL, EMBASE, PAIS Index, Cochrane Central Register of Controlled Trials, Web of Science, and PubMed). We identified studies that (1) clearly described a government policy intervention aimed at reducing human antimicrobial use, and (2) applied a quantitative design to measure the impact. We found 69 unique evaluations of government policy interventions carried out across 4 of the 6 WHO regions. These evaluations included randomized controlled trials (n = 4), non-randomized controlled trials (n = 3), controlled before-and-after designs (n = 7), interrupted time series designs (n = 25), uncontrolled before-and-after designs (n = 18), descriptive designs (n = 10), and cohort designs (n = 2). From these we identified 17 unique policy options for governments to reduce the human use of antimicrobials. Many studies evaluated public awareness campaigns (n = 17) and antimicrobial guidelines (n = 13); however, others offered different policy options such as professional regulation, restricted reimbursement, pay for performance, and prescription requirements. Identifying these policies can inform the development of future policies and evaluations in different contexts and health systems. Limitations of our study include the possible omission of unpublished initiatives, and that policies not evaluated with respect to antimicrobial use have not been captured in this review. CONCLUSIONS: To our knowledge this is the first study to provide policy makers with synthesized evidence on specific government policy interventions addressing AMR. In the future, governments should ensure that AMR policy interventions are evaluated using rigorous study designs and that study results are published. more

Download (69)

View PDF (111)

Considerations on the Use of Antivirals, Monoclonal Antibodies, and Other Interventions for the Management of COVID-19 Patients in Latin America and the Caribbean

World Health Organization WHO; PAHO; et al. (2022) CC

May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently,... more

Download (33)

View PDF (565)

Fexinidazole for Human African Trypanosomiasis, the Fruit of a Successful Public-Private Partnership.

Bernhard, S.; Kaiser, M.; Burri, C.; Mäser, P. Diseases (2022) CC

After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge... more

Download (64)

View PDF (411)

National Guidelines for Diabetic Eye Care

Ministry of Health Malawi (2021) CC

Diabetes mellitus (DM) is a global epidemic with significant morbidity. Diabetic retinopathy (DR) is the specific microvascular complication of DM and affects 1 in 3 persons with DM. DR remains a leading cause of vision loss in working adult populations. Patients with severe levels of DR are report... more

Download (143)

View PDF (156)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Optimized Supportive Care for Ebola Virus Disease recommended

WHO Living guideline: Drugs to prevent COVID-19 recommended

A living WHO guideline on drugs for covid-19 recommended

Optimized Supportive Care for Ebola Virus Disease
recommended

WHO Living guideline: Drugs to prevent COVID-19
recommended

A living WHO guideline on drugs for covid-19
recommended